Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,184 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo 4-weeks Clear all
Completed Phase 2Phase 3 Interventional

Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism

NCT00273650
View directory record Official record
Conditions
Autistic Disorder
Interventions
methylcobalamin, saline placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 8 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Constipation Fiber Trial

NCT02193997
View directory record Official record
Conditions
Functional Constipation in Children
Interventions
Fiber, Placebo
Other
Lead sponsor
Warren Bishop
Other
Eligibility
2 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

NCT03902080
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
75
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Study Of Adults And Adolescents With Vasomotor Rhinitis

NCT00117325
View directory record Official record
Conditions
Rhinitis, Vasomotor
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
38
States / cities
Beverly Hills, California • Huntington Beach, California • Mission Viejo, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 3, 2026, 2:34 AM EDT
Recruiting Phase 3 Interventional

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
ICS-LABA, benralizumab, Placebo for Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 3, 2026, 2:34 AM EDT
Terminated Not applicable Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT03020797
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Perampanel, Placebo Oral Tablet
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 3, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional

Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

NCT06982820
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Prism Training
Device
Lead sponsor
GrayMatters Health Ltd.
Industry
Eligibility
22 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Providence, Rhode Island • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT02105948
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Newport Beach, California • Rochester, Minnesota • Saint Charles, Missouri + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

NCT02219685
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

NCT03574597
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
17,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
205
States / cities
Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 163 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Sep 3, 2026, 2:34 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

NCT03607643
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions
Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide
Drug
Lead sponsor
Leaf Vertical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

NCT04707313
View directory record Official record
Conditions
Obesity
Interventions
Placebo (Cohorts 1 and 2), PF-06882961 (Cohorts 1 and 2), Placebo (Cohort 3), PF-06882961 (Cohort 3)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
27
States / cities
Anniston, Alabama • Anaheim, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 3, 2026, 2:34 AM EDT
Terminated Phase 1 Interventional

Study of Fish Oil to Reduce ALT Levels in Adolescents

NCT00694746
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 3, 2026, 2:34 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin D Intervention and Associated Changes in the Gut Microbiome and Vitamin D Levels in Healthy Adults

NCT05387876
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Vitamin D intervention, Placebo intervention
Dietary Supplement
Lead sponsor
Baylor University
Other
Eligibility
18 Years to 79 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 1Phase 2 Interventional

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

NCT00957918
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine, placebo comparator
Drug · Other
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 83 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Effect of Low Level Laser Light on Low Back Pain

NCT02538523
View directory record Official record
Conditions
Low Back Pain
Interventions
Erchonia FX-635, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Chandler, Arizona • San Mateo, California • Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Results available

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

NCT04676646
View directory record Official record
Conditions
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Interventions
Sodium zirconium cyclosilicate, Placebo, Spironolactone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Fairhope, Alabama • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 3, 2026, 2:34 AM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
5 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole in Children and Adolescents With Bipolar I Disorder

NCT00110461
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
53
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

NCT03461861
View directory record Official record
Conditions
APOE 4
Interventions
AGB101 220 mg, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
55 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

NCT02706717
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Visbiome Extra Strength, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 3, 2026, 2:34 AM EDT
Terminated Phase 2Phase 3 Interventional

Lamictal in the Treatment of Post-Herpetic Neuralgia

NCT00295776
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
Lamictal in the treatment of Post-Herpetic Neuralgia
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 85 Years
Timeline
Started 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Sep 3, 2026, 2:34 AM EDT
Completed Phase 2Phase 3 Interventional

Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke

NCT00933868
View directory record Official record
Conditions
Stroke
Interventions
Magnesium Chloride, Placebo
Drug
Lead sponsor
Relox Medical, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Grand Rapids, Michigan • Suffern, New York • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Sep 3, 2026, 2:34 AM EDT